Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (545)	7/18/2006 1:12:15 PM
From: Jibacoa	Respond to of 802

Panel of Experts to Review Positive Clinical Data Regarding Introgen's ADVEXIN Tuesday July 18, 11:46 am ET Investigators Will Participate in Conference Call Today at 4:30 p.m. ET AUSTIN, Texas, July 18 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) will conduct a conference call today at 4:30 p.m. ET to discuss data regarding Introgen's lead product ADVEXIN® presented at the annual meetings of the American Society of Gene Therapy (ASGT) and the American Society of Clinical Oncology (ASCO). A panel of clinical experts will discuss the importance of prognostic indicators of ADVEXIN efficacy associated with high response rates, locoregional disease control and increased survival from Introgen's ADVEXIN program. Conference Call Information Date / Time: July 18, 2006 at 4:30 p.m. ET Participant Dial-in numbers: (877) 616-4476 U.S. and Canada (706) 679-7372 International This call is also being web cast and can be accessed at Introgen's web site at introgen.com . A web cast replay will be available at introgen.com . The call will be hosted by David Nance, President and CEO, Robert E. Sobol, M.D., Introgen's senior vice president, Medical and Scientific Affairs, and Max W. Talbott, Ph.D., Introgen's senior vice president for Regulatory and Worldwide Commercial Development. They will be joined by several investigators with first hand experience using ADVEXIN in clinical trials. Scheduled to participate in the discussion are: Dr. John Nemunaitis, Executive Director of the Baylor College Mary Crowley Medical Research Center in Dallas; Dr. Neil Senzer, Scientific Director, Mary Crowley Medical Research Center in Dallas; Dr. John T. Hamm, Medical Director of the Louisville Oncology Research Program; and, Dr. W. Jarrard Goodwin, Director, Sylvester Comprehensive Cancer Center of the University of Miami. The call will include detailed discussions of the significance and clinical application of biomarkers predictive of ADVEXIN efficacy. The identification of prognostic indicators of ADVEXIN activity complies with initiatives of regulatory agencies to identify biomarkers that can predict the patient populations most likely to benefit from a specific cancer therapy. In blinded analyses performed by an independent testing laboratory, a molecular biomarker was identified that predicted patients most likely to benefit from ADVEXIN cancer therapy. This biomarker also identifies patients who are less likely to respond to standard cancer treatment. The predictive biomarkers correlated with statistically significant increases in survival, tumor response and loco-regional disease control following ADVEXIN therapy in clinical trials. The predictive use of biomarkers coincides with Food and Drug Administration as well as with National Cancer Institute initiatives on the use of biomarkers in the development of breakthrough cancer therapies. In addition, Introgen will discuss the successful use of ADVEXIN for Li- Fraumeni Syndrome cancer, an inherited form of malignancy characterized by the loss of p53 tumor suppressor protection. Snip Bernard